LPP SA designs, manufactures, and distributes apparel for women, men, and children. It offers apparel, accessories, footwear, and supplementary items under the Reserved, Cropp, House, Mohito, and Sinsay brand names. The …
Industry Peers
Apparel Manufacturing| Headline | Source | Time |
|---|---|---|
This week | ||
PParkiet | ||
Older | ||
PParkiet | ||
RRzeczpospolita | ||
BBusiness Insider Polska | ||
SStrefa Inwestorów | ||
BBIZNES24 | ||
SStrefa Inwestorów | ||
RRzeczpospolita | ||
PParkiet | ||
NNext Gazeta.pl | ||
SStrefa Inwestorów | ||
SStrefa Inwestorów | ||
SStrefa Inwestorów | ||
SStrefa Inwestorów | ||
SStrefa Inwestorów | ||
BBIZNES24 | ||
BBIZNES24 | ||
LPP SA (WAR:LPP) Full Year 2025 Earnings Call Highlights: Record Growth and Strategic ... LPP SA (WAR:LPP) reports a robust 19% revenue increase, significant store expansion, and strategic investments in logistics and automation, setting the stage for future growth. | ||
LPP shares surge as Q3 profit jumps on strong sales growth Investing.com - Polish fashion retailer LPP SA (WA:LPPP) on Thursday reported a 39% increase in third-quarter net profit to PLN 800 million as revenue climbed 22% YoY to over PLN 6 billion, driven by strong performance across both online and physical store channels. | ||
Heineken’s Strongbow adds NaviLens levels to packaging The cider brand has added a high-contrast NaviLens QR code to its cans. | ||
3 firms to lay off hundreds of North Jersey-based employees BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty | ||
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||